

# Hanbo Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2713372/publications.pdf>

Version: 2024-02-01

17  
papers

641  
citations

858243

12  
h-index

993246

17  
g-index

20  
all docs

20  
docs citations

20  
times ranked

892  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies. <i>BMC Pulmonary Medicine</i> , 2022, 22, 14.	0.8	9
2	Serum levels of anti-transcriptional intermediary factor 1- $\beta$ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152011.	1.6	4
3	Clinical features, treatments and outcomes of calcinosis in adult patients with dermatomyositis: a single cohort study. <i>Rheumatology</i> , 2021, 60, 2958-2962.	0.9	7
4	Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis. <i>Arthritis Research and Therapy</i> , 2021, 23, 15.	1.6	14
5	Muscle pathological features and extra-muscle involvement in idiopathic inflammatory myopathies with anti-mitochondrial antibody. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 741-748.	1.6	16
6	Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome. <i>Clinical Rheumatology</i> , 2020, 39, 2417-2424.	1.0	14
7	The RIG-I pathway is involved in peripheral T cell lymphopenia in patients with dermatomyositis. <i>Arthritis Research and Therapy</i> , 2019, 21, 131.	1.6	17
8	The Regulatory T Cell in Active Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2019, 10, 159.	2.2	61
9	Specific Autoantibodies and Clinical Phenotypes Correlate with the Aberrant Expression of Immune-Related MicroRNAs in Dermatomyositis. <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	0.9	14
10	The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. <i>Clinical Rheumatology</i> , 2019, 38, 2171-2179.	1.0	41
11	Differential Clinical Associations of Anti- $\alpha$ -Nuclear Matrix Protein 2 Autoantibodies in Patients With Idiopathic Inflammatory Myopathies. <i>Arthritis and Rheumatology</i> , 2018, 70, 1288-1297.	2.9	20
12	Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis. <i>Journal of Rheumatology</i> , 2018, 45, 835-840.	1.0	23
13	Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies. <i>Journal of Rheumatology</i> , 2017, 44, 1051-1057.	1.0	123
14	Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2017, 19, 259.	1.6	134
15	Significant decrease in peripheral regulatory B cells is an immunopathogenic feature of dermatomyositis. <i>Scientific Reports</i> , 2016, 6, 27479.	1.6	29
16	The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis. <i>Clinical Rheumatology</i> , 2016, 35, 2715-2721.	1.0	19
17	Factors Predicting Malignancy in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e94128.	1.1	96